Natural product-based therapy for Hepatocellular carcinoma: Asprin [acetylsalicylic acid (ASA) ] increases the expression of hepatocellular carcinoma, downregulated 1 (HEPN1) and inhibits the progression of hepatocellular carcinoma via down regulation of its target gene, 24/February/2015, 22.33

Molecular therapy for Myocardial Infarction: Deubiquitylase HAUSP improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 24/February/2015, 22.16
February 24, 2015
Mechanistic insights into tumor suppression: Ribosomal protein S14 increases the expression of tumor suppressor PTEN via down regulation of its target gene, 25/February/2015, 5.43 am
February 25, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Natural product-based therapy for Hepatocellular carcinoma: Asprin [acetylsalicylic acid (ASA)] increases  the expression of hepatocellular carcinoma, downregulated 1 (HEPN1) and inhibits the progression of hepatocellular carcinoma via down regulation of its target gene, 24/February/2015, 22.33, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that Asprin [acetylsalicylic acid (ASA) ]by decreasing the expression of its target gene, it may increase the expression of HEPN1. Thereby, it may inhibit the progression of Hepatocellular carcinoma. Thus, pharmacological formulations encompassing “asprin or its analogues”  can be used to treat Hepatocellular carcinoma.

Amount: $ 300

Undisclosed information: How aspirin  increases the expression of HEPN1

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.